z-logo
Premium
National patterns of medication use during pregnancy
Author(s) -
Lee Euni,
Maneno Mary K.,
Smith Leah,
Weiss Sheila R.,
Zuckerman Ilene H.,
Wutoh Anthony K.,
Xue Zhenyi
Publication year - 2006
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.1241
Subject(s) - medicine , pregnancy , medical prescription , ambulatory , specialty , family medicine , pharmacoepidemiology , genetics , pharmacology , biology
Purpose To describe patterns of medication use during pregnancy in ambulatory care settings according to the U.S. Food and Drug Administration (FDA) pregnancy risk classification. Methods A cross‐sectional study of two national ambulatory care surveys, sampling all office visits made by pregnant women in 1999 and 2000, was conducted. Using the FDA pregnancy risk classification, patterns of medication use and predictive factors for FDA pregnancy risk D or X (D/X) medications were evaluated. Results In 1999 and 2000, about half of all pregnant visits had one or more medications. Among the total visits, FDA Class A was the majority (private = 65.7%; hospital = 79.5%; p  < 0.05) followed by Class C (private = 26.5%; hospital = 36.4%; p  < 0.05). Class D/X medications accounted for 6.4% and 2.9% of visits in private and hospital, respectively ( p  < 0.05). Medications with unknown pregnancy categories were predominant in the private setting (12.0% and 3.9%; p  < 0.05). Age, insurance type, region, physician specialty, and number of medications were associated with a category D/X prescription. Among hospital visits, those from the West region and with private insurance were more likely to receive category D/X prescriptions. Number of medications was strongly associated with high‐risk drugs in both settings. Conclusions This study shows considerable medication use among pregnant women. The prevalence of visits with FDA pregnancy category D/X drugs was moderate, but still indicates exposure to high‐risk medications. Copyright © 2006 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here